Cyclerion Therapeutics Inc (CYCN)
| Sector • Healthcare Industry • Major Pharmaceutical Preparations |
| Industry • Major Pharmaceutical Preparations |
| Sector • Healthcare |
Fading Deficit at the CYCN in fourth quarter of 2022 earnings season
company delivered fourth quarter of 2022 operating shortfall of $-7.348 million
Published 2023-03-23T11:12:39+00:00
Goran Soko / CSIMarket.com Contributer
![pills_blue_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills_blue_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg "pills_blue_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
For the fourth quarter of 2022 earnings season company decreased a loss per share of $-0.17 per share compare to $-0.25 a year prior and EPS improved from $-0.24 per share from the previous reporting season. The revenue were up by 14.286 % to $0.61 million from $0.53 million in the same reporting season a year prior and sequentially from $0.00 million.
In the fourth quarter of 2022 earnings season Cyclerion Therapeutics Inc reported net deficit of $-7.216 million, instead of deficit of $-10.776 million in the same reporting season a year ago.
Additionally, the CYCN noted also a shortfall of $-44.08 million and for the financial year 2022, revenue of $1.63 million.
Major Pharmaceutical Preparations The Major Pharmaceutical Preparations company has decreased it's deficit per share to $-1.01 from $-1.32 in the previous fiscal year, while Revenue Tumbled by -58.78 % from $3.94 million a year prior.
Cyclerion Therapeutics Inc is expected to report next financial earnings on August 08, 2023.
Other CYCN's Earnings Reports
A deficit of $-0.31 per Share at the Cyclerion Therapeutics Inc during the second quarter of 2022
Other CYCN's Earnings Reports
A deficit of $-0.31 per Share at the Cyclerion Therapeutics Inc during the second quarter of 2022